Mitosis-targeted anti-cancer therapies: where they stand

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

(2012) E. Komlodi-Pasztor et al.   CLINICAL CANCER RESEARCH

The Centrosome: A Target for Cancer Therapy

(2012) M. Mazzorana et al.   CURRENT CANCER DRUG TARGETS

Novel Drugs Targeting Microtubules: the Role of Epothilones

(2012) Gabriella Ferrandina et al.   CURRENT PHARMACEUTICAL DESIGN

Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside

(2012) A. R. Mato et al.   ONCOLOGIST

Survivin in Solid Tumors: Rationale for Development of Inhibitors

(2012) David N. Church et al.   Current Oncology Reports

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

(2011) Henry L. Gomez et al.   ANTI-CANCER DRUGS

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

(2011) Elaina M. Gartner et al.   BREAST CANCER RESEARCH AND TREATMENT

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

(2011) J. R. Infante et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

(2011) Vincent Chung et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells

(2011) Guangmin Xi et al.   CANCER LETTERS

Disturbance in function and expression of condensin affects chromosome compaction in HeLa cells

(2011) Lei Zhai et al.   CELL BIOLOGY INTERNATIONAL

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy

(2011) Linda Smolders et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma

(2011) Andrea E. Wahner Hendrickson et al.   GYNECOLOGIC ONCOLOGY

Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

(2011) Maria-Elena Theoclitou et al.   JOURNAL OF MEDICINAL CHEMISTRY

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

(2011) Y. Hikichi et al.   MOLECULAR CANCER THERAPEUTICS

Spindle Poisons and Cell Fate: A Tale of Two Pathways

(2011) D. R. Matson et al.   MOLECULAR INTERVENTIONS

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes

(2011) Ja-Lok Ku et al.   CELLULAR ONCOLOGY

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma

(2010) Gary A. Croghan et al.   CANCER

Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage

(2010) Xing Zeng et al.   CANCER CELL

Targeting Mitotic Exit Leads to Tumor Regression In Vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ Phosphatase

(2010) Eusebio Manchado et al.   CANCER CELL

Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase

(2010) R. Colombo et al.   CANCER RESEARCH

Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy

(2010) Sarah E. McClelland et al.   CELL CYCLE

Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death

(2010) S-K Lai et al.   CELL DEATH AND DIFFERENTIATION

Establishment of a new Philadelphia chromosome−positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation

(2010) Seiichi Okabe et al.   EXPERIMENTAL HEMATOLOGY

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

(2010) Tianhong Li et al.   INVESTIGATIONAL NEW DRUGS

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

(2010) Howard A. Burris et al.   INVESTIGATIONAL NEW DRUGS

A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium study

(2010) Abdul-Kader Souid et al.   PEDIATRIC BLOOD & CANCER

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

(2010) K. W. Wood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis

(2010) K-S Chan et al.   Cell Death & Disease

Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl- l -cysteine in tumor derived cell lines

(2009) Sergey Tcherniuk et al.   BIOCHEMICAL PHARMACOLOGY

Kinesin motor proteins as targets for cancer therapy

(2009) Dennis Huszar et al.   CANCER AND METASTASIS REVIEWS

Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly

(2009) Hsiao-Chun Huang et al.   CANCER CELL

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

(2009) Shivaani Kummar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Correcting aberrant kinetochore microtubule attachments: an Aurora B-centric view

(2009) Alexander E Kelly et al.   CURRENT OPINION IN CELL BIOLOGY

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

(2009) N Raje et al.   LEUKEMIA

Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy

(2009) Yingmei Wang et al.   Molecular Cancer

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells

(2009) Aniek Janssen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

Rhabdoid Tumor Growth is Inhibited by Flavopiridol

(2008) M. E. Smith et al.   CLINICAL CANCER RESEARCH

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

(2008) S. Cresta et al.   EUROPEAN JOURNAL OF CANCER

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

(2008) E. Walsby et al.   HAEMATOLOGICA

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells

(2008) L. Shen et al.   MOLECULAR CANCER THERAPEUTICS

Apoptotic histone modification inhibits nuclear transport by regulating RCC1

(2008) Chi-Hang Wong et al.   NATURE CELL BIOLOGY

Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells

(2008) Eun Jeong Choi et al.   PHYTOMEDICINE

Flavopiridol displays preclinical activity in acute lymphoblastic leukemia

(2007) Kelly M. Jackman et al.   PEDIATRIC BLOOD & CANCER

Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways

(2003) Sai Latha Shankar et al.   JOURNAL OF NEUROCHEMISTRY